CHICAGO — Sophia Randolph, MD, PhD, chief medical officer at Alexo Therapeutics, spoke with HemOnc Today at ASCO Annual Meeting about ALX148.
The anti-CD47 fusion protein is in development for treatment of patients with advanced solid tumors, as well as those with non-Hodgkin lymphoma.
“CD47 is among the most interesting novel targets being explored in oncology today because of its central role in mediating immune response against cancer,” Randolph told HemOnc Today.
At ASCO, researchers presented data from a first-in-human trial of ALX148 that showed the agent is well tolerated. Investigators did not reach a maximum tolerated dose with the agent as monotherapy or as part of combination treatment.
The maximum administered dose will be used in the next phase of the trial, which will include expansion cohorts designed to assess ALX148 in combination with pembrolizumab (Keytruda, Merck), rituximab (Rituxan; Genentech, Biogen) or trastuzumab (Herceptin, Genentech) in specific tumor types.
Randolph also highlighted the key three ways that ALX148 differs from other CD47-targeted agents.